인슐린 비치료 2형 당뇨병용 CGM 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 용도별, 연결 방식별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

CGM For Non-Insulin-Treated Type 2 Diabetes Market Summary

The global CGM for non-insulin-treated Type 2 diabetes market size was valued at USD 1.4 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 3.5 billion by 2033, at a CAGR of 10.2% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 73.7% in 2025. The global CGM for non-insulin-treated Type 2 diabetes market is experiencing strong growth, driven by rising prevalence of Type 2 diabetes, growing clinical evidence supporting CGM use among non-insulin-treated patients, expanding guideline recognition, increasing adoption of over-the-counter (OTC) CGM systems, and greater consumer awareness of continuous glucose monitoring insights.

Recent evidence shows that CGM can improve HbA1c and time in range in non-insulin-treated patients, while the 2025 ADA Standards of Care expanded consideration of CGM for adults using non-insulin therapies. The emergence of OTC platforms is also lowering access barriers and broadening CGM beyond traditional prescription-based diabetes management toward lifestyle, nutrition, fitness, and metabolic-health monitoring.

The role of continuous glucose monitoring (CGM) is expanding beyond insulin-treated diabetes, with emerging clinical evidence supporting its use among adults with type 2 diabetes (T2D) who are not using insulin. New findings presented at the American Diabetes Association (ADA) 2026 Scientific Sessions indicate that CGM can significantly improve glycemic control in this population, strengthening the clinical rationale for broader adoption of CGM in primary care.

The CONNECT randomized controlled trial evaluated 283 adults with non-insulin-treated T2D across 22 U.S. primary care practices over 26 weeks. Participants had a mean baseline A1C of 8.8%, with nearly one-third having A1C levels of at least 9%. Patients were randomized to use the Dexcom G7 CGM or receive routine care using standard blood glucose meter testing. The study found that 82% of adults using CGM improved their blood glucose levels, while CGM use produced a 0.9 percentage-point greater reduction in A1C compared with routine care. Participants also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL.

Global CGM for Non-Insulin-Treated Type 2 Diabetes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global CGM for non-insulin-treated Type 2 diabetes market report based on product, application, connectivity, distribution channel, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Sensor
• Applicator
• Transmitter
• Device / Reader
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Glucose / Diabetes Management
• Lifestyle Monitoring
• Diet & Nutrition Monitoring
• Physical Activity & Fitness Monitoring
• Weight Management
• Connectivity Outlook (Revenue, USD Billion, 2021 - 2033)
• Bluetooth
• 4G / Cellular
• NFC
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmacies
• E-commerce
• Others
• Region Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Thailand
  • Singapore
  • Malaysia
  • Taiwan
  • Vietnam
  • Philippines
• Latin America
  • Brazil
  • Argentina
• MEA
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Connectivity
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Connectivity outlook
  • 2.2.4. Distribution Channel outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. CGM for Non-Insulin-Treated Type 2 Diabetes Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Product Movement Analysis
• 4.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Sensor
  • 4.5.1. Sensor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Applicator
  • 4.6.1. Applicator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Transmitter
  • 4.7.1. Transmitter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Device / Reader
  • 4.8.1. Device / Reader Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Application Movement Analysis
• 5.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Glucose / Diabetes Management
  • 5.5.1. Glucose / Diabetes Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Lifestyle Monitoring
  • 5.6.1. Lifestyle Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Diet & Nutrition Monitoring
  • 5.7.1. Diet & Nutrition Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Physical Activity & Fitness Monitoring
  • 5.8.1. Physical Activity & Fitness Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Weight Management
  • 5.9.1. Weight Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Connectivity Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Connectivity Movement Analysis
• 6.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Connectivity Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Bluetooth
  • 6.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. 4G / Cellular
  • 6.6.1. 4G / Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. NFC
  • 6.7.1. NFC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Distribution Channel Movement Analysis
• 7.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market by Distribution Channel Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Pharmacies
  • 7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. E-commerce
  • 7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional CGM for Non-Insulin-Treated Type 2 Diabetes Market Movement Analysis
• 8.3. CGM for Non-Insulin-Treated Type 2 Diabetes Market: Regional Estimates & Trend Analysis by Product & Source
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Mexico CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Europe
  • 8.5.6. Europe CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. UK
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. UK CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Germany
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Germany CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. France
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement scenario
    • 8.5.9.5. France CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.10. Italy
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Reimbursement scenario
    • 8.5.10.5. Italy CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.11. Spain
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Reimbursement scenario
    • 8.5.11.5. Spain CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.12. Russia
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Reimbursement scenario
    • 8.5.12.5. Russia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.13. Denmark
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Reimbursement scenario
    • 8.5.13.5. Denmark CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.14. Sweden
    • 8.5.14.1. Key Country Dynamics
    • 8.5.14.2. Competitive Scenario
    • 8.5.14.3. Regulatory Framework
    • 8.5.14.4. Reimbursement scenario
    • 8.5.14.5. Sweden CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.15. Norway
    • 8.5.15.1. Key Country Dynamics
    • 8.5.15.2. Competitive Scenario
    • 8.5.15.3. Regulatory Framework
    • 8.5.15.4. Reimbursement scenario
    • 8.5.15.5. Norway CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. Japan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. China CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. India CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement scenario
    • 8.6.6.5. Australia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement scenario
    • 8.6.7.5. Thailand CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.8. Singapore
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Reimbursement scenario
    • 8.6.8.5. Singapore CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.9. Malaysia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Reimbursement scenario
    • 8.6.9.5. Malaysia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.10. Taiwan
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Reimbursement scenario
    • 8.6.10.5. Taiwan CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.11. Vietnam
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Reimbursement scenario
    • 8.6.11.5. Vietnam CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.12. Philippines
    • 8.6.12.1. Key Country Dynamics
    • 8.6.12.2. Competitive Scenario
    • 8.6.12.3. Regulatory Framework
    • 8.6.12.4. Reimbursement scenario
    • 8.6.12.5. Philippines CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Brazil CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. Argentina CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. South Africa CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. Saudi Arabia CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. UAE CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement scenario
    • 8.8.5.5. Kuwait CGM for Non-Insulin-Treated Type 2 Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Dexcom
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Product Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Abbott Laboratories
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Product Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Medtronic plc
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Product Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. Sinocare, Inc. (iCan CGM)
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Product Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. GlucoRx Limited (AiDEX, Vixxa)
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Product Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Bionime (RIGHTEST iFree CGM)
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Product Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Nemaura
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Product Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. i-SENS, Inc.
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Product Benchmarking
    • 9.2.8.4. Strategic Initiatives